Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)
Analysts from Warburg Research and Deutsche Bank maintained a Buy rating for Medios AG, with price targets of EUR20.00 and EUR16.00 respectively, projecting a significant upside from current levels. Similarly, Stifel Nicolaus and Raymond James reiterated Buy ratings for Dyne Therapeutics, setting a price target of $37.00 and expecting a substantial upside. Both companies received a "Strong Buy" analyst consensus rating.
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the biotech company released additional one-year data from its Phase 1/2 ACHIEVE study for DM1 patients. Despite a 17% year-to-date stock decline, shares are up 28% over the past year. The company's financial position is strong, with more cash than debt, as it progresses towards regulatory milestones, though some analysts have adjusted price targets due to Novartis's recent trial failure in a similar study.
Dyne Therapeutics, Inc. (DYN) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Dyne Therapeutics, Inc. (DYN) stock, including its current price, after-hours trading, and key historical data. The page displays the stock's performance range, volume, market capitalization, and various financial metrics. It also offers sections for news, charts, community discussions, and detailed financial analysis.
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
This article states that Chardan Capital has maintained its "Buy" rating for Dyne Therapeutics. No further details about the company, the analyst's rationale, or financial data are provided in the current content.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc (NASDAQ:DYN) shares increased by 2.1% after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements across multiple measures at 12 months, including a significant decrease in video hand opening time. The company anticipates topline data in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
DYN Maintained by Chardan Capital -- Price Target Holds at $38
Chardan Capital has maintained a "Buy" rating for Dyne Therapeutics (DYN) with a price target of $38.00, suggesting the stock is currently undervalued compared to its market price of $16.21. Dyne Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapies for genetically driven neuromuscular diseases, but faces challenges with profitability and substantial insider selling. The company's GF Score is 40/100, indicating mixed financial health with strong momentum but weak profitability.
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target
Chardan Capital has reiterated its Buy rating on Dyne Therapeutics (DYN) and set a price target of $38.00, representing a significant upside of 134.4% from its recent closing price. The positive outlook is attributed to promising clinical data showing improvements in muscle function and a valuable pipeline with potential for market exclusivity through orphan drug designations.
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data?
Dyne Therapeutics (DYN) recently released positive one-year efficacy data from its ACHIEVE trial for myotonic dystrophy type 1, showing sustained functional gains and a clean safety profile. Despite this clinical success, the company's share price has seen a significant short-term pullback. The article discusses whether this pullback presents a buying opportunity or reflects concerns about the drug platform's valuation, cash burn, and execution risks for future product launches.
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced additional one-year efficacy data from its Phase 1/2 ACHIEVE clinical trial of z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1), showing functional improvement across multiple measures. The data, presented at the World Muscle Society and AANEM meetings, indicated sustained improvements in myotonia, function, strength, and patient-reported outcomes compared to baseline, placebo, and matched natural history cohorts. Dyne expects topline data from the ACHIEVE registrational expansion cohort in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced additional one-year efficacy data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1 (DM1), showing functional improvements in walking, muscle strength, and patient-reported outcomes. The pooled data, presented at medical conferences, demonstrated sustained benefits compared to baseline, placebo, and natural history cohorts, with a favorable safety profile. Dyne anticipates registrational expansion cohort topline data in Q1 2027, aiming for a potential U.S. Accelerated Approval application in Q3 2027.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc. (NASDAQ:DYN) shares rose after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements at 12 months, including decreased video hand opening time and improvements in sit-to-stand and walk/run tests. The company anticipates topline data in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc. (NASDAQ: DYN) shares rose after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements, including decreases in video hand opening time and improvements in muscle strength. The company expects topline data from the registrational expansion cohort in Q1 2027, aiming for a U.S. Accelerated Approval submission in Q3 2027.
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence
Piper Sandler has reiterated an Overweight rating and a $47.00 price target for Dyne Therapeutics (NASDAQ:DYN), expressing confidence in the accelerated approval of Zeleciment rostudirsen for DMD boys by the January 21 PDUFA date. Despite a year-to-date stock decline of 16.46%, the company's financial health is strong, holding more cash than debt and a current ratio of 12.02. Upcoming presentations of 1-year Phase I Zeleciment basivarsen data are anticipated, while recent analyst updates show a mixed but cautiously optimistic outlook for Dyne Therapeutics.
Is Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations?
Dyne Therapeutics (DYN) is gaining attention due to upcoming presentations of one-year clinical data from its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1. Despite recent share price declines, the company's valuation metrics and a Discounted Cash Flow model suggest it might be undervalued, trading below an estimated future cash flow value of $31.57 compared to its current share price of $17.12. The market appears to be pricing in significant future expectations based on its pipeline and intellectual property rather than current income, leading to a mixed valuation picture.
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026.
Dyne Therapeutics, Inc. has certain stock options subject to a lock-up agreement that ends on September 20, 2026. This agreement restricts the company's directors and officers from selling or transferring shares or related securities for 60 days following a prospectus supplement. The lock-up period began on July 21, 2026.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics has announced inducement equity awards for 14 new hires, comprising stock options for 278,100 shares and restricted stock units for 88,400 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are intended to attract new talent to the clinical-stage company. The awards vest over four years, subject to continued employment, and are part of Dyne's 2024 Inducement Stock Incentive Plan.
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
Dyne Therapeutics (DYN) will present new one-year clinical data from its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1 (DM1) in late September and early October 2026. These presentations will include functional and safety data, details from a natural history cohort, and information on a fully enrolled registrational expansion cohort. The article examines how these expanded data, especially long-term functional outcomes, might impact Dyne's investment narrative, despite current financial risks and a potentially overvalued stock.
New Dyne hires receive stock tied to 278,100 shares
Dyne Therapeutics (DYN) has granted inducement equity awards to 14 new employees, including non-statutory stock options for up to 278,100 shares and restricted stock units for 88,400 shares. These awards are part of the company's 2024 Inducement Stock Incentive Plan and are designed to vest over four years, subject to continued employment. This move aims to attract and retain talent in accordance with Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at upcoming medical meetings, including the World Muscle Society (WMS) and the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). The presentations will include data from a pooled dose group and a propensity-matched natural history cohort, along with updated safety data. Dyne also plans to provide baseline video hand opening time (vHOT) for the ACHIEVE registrational expansion cohort, with topline data expected in Q1 2027.
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure
Dyne Therapeutics' shares dropped significantly after Novartis's Del-Desiran failed its Phase 3 trial for myotonic dystrophy type 1. Despite the stock plunge, retail sentiment shifted to "extremely bullish," with some investors viewing it as a buying opportunity. Analysts have divergent views, with RBC Capital cutting its price target but maintaining an 'Outperform' rating, while Morgan Stanley also lowered its target but kept an 'Overweight' rating, emphasizing Dyne's unique program potential.
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Shares of Dyne Therapeutics (DYN) saw a sell-off after Novartis's Phase 3 study for myotonic dystrophy type 1 (DM1) failed, raising concerns for Dyne's similar experimental drug. However, RBC Capital and Morgan Stanley maintained positive ratings on DYN, highlighting key differences in drug targets, payloads, and trial designs that could lead to better outcomes for Dyne. Despite the market reaction, retail sentiment on Stocktwits remained bullish, viewing the dip as a buying opportunity.
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at upcoming medical meetings, including the World Muscle Society and AANEM. The presentations will feature 6 and 12-month data from a pooled dose group compared against a matched natural history cohort, along with updated safety data. Dyne also plans to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort, with topline data from this cohort expected in Q1 2027.
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen) for Myotonic Dystrophy Type 1 (DM1) at upcoming medical meetings. The presentations will include pooled dose group data compared to a natural history cohort, updated safety data, and the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort. Topline data from the ACHIEVE registrational expansion cohort are expected in Q1 2027.
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics (NASDAQ: DYN) shares fell after Novartis's Phase 3 HARBOR study for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint. Dyne, which is developing zeleciment basivarsen (z-basivarsen) for DM1, plans to present additional one-year clinical data from its Phase 1/2 ACHIEVE trial and has initiated its own Phase 3 HARMONIA trial for the same condition. The market reacted negatively to the competitor's trial outcome, impacting Dyne Therapeutics' stock price.
Dyne Therapeutics stock faces pressure after rival drug fails trial
Dyne Therapeutics Inc. shares are expected to face pressure after Novartis's del-desiran failed its Phase 3 trial for DM1, despite Dyne's stock delivering an 83% return over the past year. Stifel suggests buying on weakness, citing Dyne's strong scientific rationale and better Phase 1/2 data for its DM1 drug. The company recently had its Biologics License Application for zeleciment rostudirsen accepted by the FDA with Priority Review and completed significant equity offerings.
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
Dyne Therapeutics (NASDAQ:DYN) shares dropped 31% in premarket trading with no clear catalyst identified. The clinical-stage biotechnology company is developing treatments for neuromuscular diseases, including z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1. The decline occurred despite broader market moves being less severe and no comparable declines in similar companies.
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics will present preclinical data for multiple Duchenne Muscular Dystrophy (DMD) development candidates (DYNE-253, DYNE-245, DYNE-244, DYNE-255) at the 27th Annual NMSG Scientific Meeting. These candidates leverage the company's FORCE™ platform, similar to their FDA-reviewed zeleciment rostudirsen for exon 51 DMD. The data supports advancing these programs, targeting different exon skipping mutations, into IND-enabling studies.
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics will present preclinical data for multiple Duchenne Muscular Dystrophy (DMD) development candidates at the 27th Annual NMSG Scientific Meeting. These candidates, DYNE-253, DYNE-245, DYNE-244, and DYNE-255, target different exon skipping amenable DMD mutations and are advancing into IND-enabling studies. The data supports the company's FORCE™ platform in delivering therapeutic payloads and driving exon skipping and dystrophin production for DMD patients.
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics will present preclinical data for multiple Duchenne Muscular Dystrophy (DMD) development candidates (DYNE-253, DYNE-245, DYNE-244, DYNE-255) at the 27th Annual NMSG Scientific Meeting. These candidates leverage the company's FORCE™ platform for exon skipping in DMD patients with various mutations and are advancing into IND-enabling studies. The data supports Dyne's strategy to expand its DMD franchise beyond zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251).
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story
Dyne Therapeutics (DYN) received U.S. FDA clearance to begin a Phase 1 trial for DYNE-302, expanding its FORCE platform to a third clinical program for facioscapulohumeral muscular dystrophy. This development, alongside a recent US$375.15 million equity raise, impacts the company's investment narrative and risk profile. While the FDA clearance adds a new potential value driver, it also increases R&D expenses, contributing to a net loss of US$178.56 million in Q2.
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN
Royal Bank of Canada significantly increased its stake in Dyne Therapeutics by 267.6% in the first quarter, acquiring an additional 49,641 shares to reach a total holding of 68,188 shares valued at $1.24 million. Despite institutional investors owning a large portion of the company (96.68%), Dyne Therapeutics reported a larger-than-expected quarterly loss of $1.08 per share. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $34.42, although insider activity shows substantial selling compared to buying over the past 90 days.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced the grant of inducement equity awards to 11 newly hired employees, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for 161,300 shares and restricted stock units for 51,200 shares, both vesting over four years. The grants are intended to attract and retain talent for the clinical-stage company focused on genetically driven neuromuscular diseases.
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN
Handelsbanken Fonder AB recently acquired 53,200 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $1.18 million, contributing to institutional investors owning 96.68% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $34.42, despite the company reporting a wider-than-expected quarterly loss and significant insider selling.
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds
Dyne Therapeutics director Jason P. Rhodes, through Atlas Venture-affiliated funds, indirectly sold 2,586,928 shares of DYN common stock on August 13-14, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on July 13, 2026, with weighted average prices ranging from approximately $25.00 to $26.20 per share. Rhodes disclaims beneficial ownership of these shares except for his pecuniary interest.
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN
Flputnam Investment Management Co. has acquired a new stake of 52,975 shares in Dyne Therapeutics, Inc., valued at approximately $1,177,000, during the second quarter. This move is part of a broader trend of institutional investment in Dyne Therapeutics, with several other large investors also increasing their positions. The company has received a "Moderate Buy" rating from analysts with a consensus target price of $34.42, despite recent insider selling by its CFO and a director.
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN
Aegis Wealth Management LLC has acquired a new stake of 150,030 shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $3.33 million, making it their 9th largest holding. Other institutional investors have also adjusted their positions in Dyne Therapeutics, with the company's stock trading up 1.8% and having a market capitalization of $4.88 billion. Analyst ratings for Dyne Therapeutics currently show a "Moderate Buy" consensus with an average price target of $34.42, despite recent insider sales and a reported earnings per share miss.
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes
Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, reported an automatic sale of 226 shares of common stock at a weighted average price of $26.28 per share on August 13, 2026. This transaction was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units under a pre-arranged Rule 10b5-1 binding contract, rather than being a discretionary trade. Following the sale, Friedl-Naderer directly holds 153,982 shares, which includes 119,928 unvested restricted stock units.
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock
Dyne Therapeutics director Jason P. Rhodes sold approximately $65.2 million worth of common stock through various Atlas Venture funds on August 13 and 14, 2026. The sales were executed under a Rule 10b5-1 trading plan as the DYN stock traded near its 52-week high. These transactions occurred amidst significant company news, including the FDA's Priority Review for its Duchenne muscular dystrophy treatment and a $375 million public stock offering.
Dyne Therapeutics (NASDAQ: DYN) CMO has shares sold for tax withholding
Dyne Therapeutics Chief Medical Officer Douglas Kerr sold 1,556 shares of common stock on August 13, 2026, at a weighted average price of $26.28 per share. This sale was non-discretionary, automatically executed to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units under a Rule 10b5-1 plan. Following the transaction, Kerr directly holds 167,599 shares, including 140,001 unvested restricted stock units.
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock
Jason P. Rhodes, a Director at Dyne Therapeutics, Inc., recently sold approximately $65.2 million worth of common stock over two days, August 13 and 14, 2026, under a pre-arranged trading plan. The shares were sold at prices ranging from $25.00 to $26.20, with the stock trading near its 52-week high and considered overvalued by InvestingPro. This comes amidst other company news, including FDA acceptance of a Biologics License Application for Duchenne muscular dystrophy and a recent $375 million public stock offering.
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock
Dyne Therapeutics CFO Erick Lucera sold $47,225 worth of company stock to cover tax withholding obligations related to restricted stock unit vesting. The sale of 1,797 shares occurred when Dyne's stock was near its 52-week high, with the company also announcing FDA Priority Review for a Duchenne muscular dystrophy treatment and recent stock offerings. Analysts have issued positive ratings for Dyne Therapeutics, which plans to release topline results from a clinical trial in Q1 2027.
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock
Dyne Therapeutics director Jason Rhodes sold over 2.16 million shares of DYN stock for approximately $54 million, reducing his direct ownership by 83.43% through a pre-arranged Rule 10b5-1 plan. Despite the significant insider selling and a recent EPS miss, Dyne Therapeutics shares rose, trading near their 52-week high. Analysts maintain a "Moderate Buy" consensus with a target price of $34.42, and institutional investors hold a substantial portion of the company's stock.
Jason Rhodes Sells 426,412 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Jason Rhodes, a director at Dyne Therapeutics (NASDAQ:DYN), sold 426,412 shares of the company's stock for approximately $11.17 million. This transaction, executed under a Rule 10b5-1 trading plan, reduced his direct ownership by 36.2%. Despite missing analyst earnings expectations, Dyne Therapeutics shares rose, trading near their 52-week high, and the company maintains a "Moderate Buy" consensus rating from analysts.
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock
Dyne Therapeutics CFO Erick Lucera sold $47,225 worth of company stock, an automatic transaction to cover tax obligations from vested restricted stock units. This sale occurred while Dyne shares were near their 52-week high, following a significant 108% return over the past year. The company recently saw its Biologics License Application accepted by the FDA for zeleciment rostudirsen with Priority Review and also priced a $375 million public stock offering.
Dyne Therapeutics (DYN) CEO's tax-driven sale to cover RSU taxes
Dyne Therapeutics (DYN) CEO & President John Cox reported an automatic sale of 4,986 shares of Common Stock on August 13, 2026, at a weighted average price of $26.28 per share. This sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 12, 2026, and was not a discretionary trade, consistent with a Rule 10b5-1 binding contract. Following the transaction, Cox directly holds 363,165 shares, including 248,314 unvested RSUs, and indirectly holds 18,000 shares in each of four trusts for the benefit of a child.
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade
Dyne Therapeutics CFO Erick Lucera sold 1,797 shares of common stock on August 13, 2026, at a weighted average price of $26.28 per share. This sale was an automatic disposition to cover tax withholding obligations upon the vesting of restricted stock units, as part of a pre-existing Rule 10b5-1 binding contract, and was not a discretionary trade. Following the transaction, Lucera directly holds 119,766 shares, including 106,451 unvested RSUs.
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook
H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Dyne Therapeutics (NASDAQ:DYN), citing the upcoming HARBOR trial data readout as a significant catalyst for DM1 treatment. The firm anticipates the HARBOR trial will meet its primary endpoint, drawing comparisons to positive results from Avidity's MARINA-OLE study. Dyne Therapeutics is also expected to release topline results from its ACHIEVE REC trial in Q1 2027, with recent activities including a $300 million equity offering and FDA Priority Review for its Duchenne muscular dystrophy treatment, z-rostudirsen.
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN
Bank of America Corp DE significantly increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 63.5% in the first quarter, now holding 1.44 million shares valued at $26.17 million. Institutional investors and hedge funds collectively own 96.68% of DYN. While a director purchased shares, the CFO sold some, resulting in insiders buying $156,800 and selling $34.26 million worth of stock during the quarter. Despite missing quarterly EPS estimates, analysts maintain a "Moderate Buy" consensus with an average price target of $34.42.
Dyne Therapeutics, Inc. SEC Filing (Aug 14, 2026)
This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on August 14, 2026. The filing indicates a proposed sale of 478,377 shares of common stock with an aggregate market value of $12,418,666.92, acquired via private placement in December 2022. The filing also notes that no securities were sold in the past three months by the person filing.
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson
Janus Henderson Group Ltd. filed an amended beneficial ownership report (SCHEDULE 13G/A) for Dyne Therapeutics Inc. (DYN), indicating that its affiliated asset managers beneficially own 11,997,738 shares, representing 7.3% of the class as of June 30, 2026. These shares are held in client Managed Portfolios, with asset managers exercising shared voting and dispositive power. Janus Henderson disclaims economic ownership, with dividends and sale proceeds going to the Managed Portfolios, none of which individually holds more than 5% of Dyne Therapeutics' common stock.
